

Allergy Therapeutics^{PLC}

Allergy Therapeutics plc
("Allergy Therapeutics" or "the Group")

Allergy Therapeutics presents scientific advancements in its pollen and food-allergy research portfolio at the 2025 AAAAI / WAO Joint Congress

27 February 2025 Allergy Therapeutics plc (AIM: AGY), the integrated commercial biotechnology company specialising in allergy immunotherapies, today announces that it will be sharing key scientific findings from across its research portfolio at the [2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization \(AAAAI / WAO\) Joint Congress](#), taking place in San Diego, California from tomorrow, 28 February, to 3 March 2025.

The 2025 AAAAI / WAO Joint Congress is a premier conference in the field of allergy, asthma and immunology, hosted by the American Academy of Allergy, Asthma & Immunology (AAAAI), a leading membership organisation of more than 7,100 allergists/immunologists, and the World Allergy Organization (WAO), an international umbrella organisation whose members consist of 115 regional and national allergology and clinical immunology societies. The congress brings together thousands of clinicians, researchers and allied health professionals from around the world who are dedicated to advancing the understanding and treatment of allergic and immunologic diseases.

Among its six posters being presented, Allergy Therapeutics will share:

- A positive comparative assessment highlighting the efficacy of the pivotal Phase III trial with Grass MATA MPL, the Group's short-course subcutaneous allergen-specific immunotherapy (SCIT) candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen, against two regulatory approved grass immunotherapy products
- Design details of the G308 Phase III trial investigating the long-term safety and efficacy of Grass MATA MPL in grass allergic children and adolescents, which began in [November 2024](#)
- Supporting safety and tolerability data from the ongoing Phase I/IIa PROTECT clinical trial of the Group's novel virus-like-particle (VLP)-based peanut allergy vaccine candidate ("VLP Peanut") in peanut allergic patients, which reported positive interim biomarker efficacy data in [December 2024](#), demonstrating the first evidence of the candidate's benign safety profile in peanut allergic patients

Manuel Llobet, Chief Executive Officer at Allergy Therapeutics, said: *"We are delighted to be showcasing our leading research at this year's AAAAI / WAO Joint Congress, with six posters that highlight our commitment to transforming patients' lives through innovative therapies. Last year's submission of our marketing authorisation application for Grass MATA MPL, the initiation of our G308 Phase III trial in paediatric patients suffering from grass pollen allergy and the positive interim data from our ongoing VLP Peanut PROTECT trial, all illustrate the strength and pace of innovation at Allergy Therapeutics. We look forward to sharing more about our progress and learning from others at this important congress."*

The complete list of Allergy Therapeutics-sponsored abstracts accepted by AAAAI / WAO for presentation are available on the Group's website.

No new material price sensitive information will be disclosed on Allergy Therapeutics at the 2025 AAAAI / WAO Joint Congress.

For further information, please contact:

Allergy Therapeutics

Manuel Llobet, Chief Executive Officer

Shaun Furlong, Chief Financial Officer

+44 (0)1903 845 820

Cavendish Capital Markets Limited (Nominated Adviser and Broker)

Geoff Nash /Giles Balleny/ Seamus Fricker / Rory Sale

Nigel Birks - Life Science Specialist Sales

Tamar Cranford Smith - Sales

+44 (0)20 7220 0500

ICR Healthcare

Mary-Jane Elliott / David Daley / Davide Salvi

+44 (0)20 3709 5700

allergytherapeutics@icrhealthcare.com

Notes for editors:**About Allergy Therapeutics**

Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapies that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. For more information, please see www.allergytherapeutics.com.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAPPUBWPUPAGMQ

